



NeuroScientific Appoints Experienced Cell Therapy Executive Nathan Smith as CEO

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**” or “**the Company**”) is pleased to announce the appointment of Mr. Nathan Smith as Chief Executive Officer, effective 28 July 2025. Based in Melbourne, Mr. Smith brings extensive experience in cell and gene therapies, having held senior commercial, operational, and strategic roles in both Australia and the United States.

Mr. Smith’s career includes leadership positions at **Cell Therapies Pty Ltd** where he served as Director of Business Development as well as key roles at **Genzyme Corporation (USA)**, **Mesoblast Inc. (USA)**, **GlaxoSmithKline (USA)**, and other leading companies in the cell therapy space. Throughout his career, Nathan has led programs across the full therapeutic lifecycle, including pre-clinical development and clinical trials, navigating the regulatory pathway in multiple jurisdictions and the commercial supply of products.

Importantly, Nathan brings deep expertise in GMP manufacturing, an essential pillar for the successful translation and scale-up of any stem cell company. His manufacturing background comes at a pivotal time for NSB as we accelerate development of our platform and prepare for future clinical trials and commercialization.

Mr. Smith said: *“I was attracted to NSB given the historical success of StemSmart in multiple serious clinical disorders and the clear potential of the technology for further development. I am excited to join NSB and to work alongside Dr. Sturm, whose clinical leadership I greatly admire. Together with the broader team, I look forward to advancing the StemSmart technology and helping make it accessible to patients with serious and life-threatening conditions.”*

Chairman Rob McKenzie added: *“Nathan’s appointment reflects the exciting trajectory of NSB following the acquisition of Isopogen’s cell therapy technology. His leadership alongside Dr. Sturm’s clinical expertise positions the Company to unlock the full potential of our pipeline and build strong relationships with future commercial partners.”*

With Nathan’s proven track record and deep understanding of the manufacturing, regulatory, and commercial aspects of cell therapy, NSB is well-positioned to scale its platform and deliver on its mission to transform patient care.

Remuneration Package

- Salary - \$250,000 per annum plus Super
- Equity Incentives to be issued under NSB's ESOP

Options

Tranche	#	Exercise Price	Vesting Period	Expiry
A	1.5 million	\$0.15	12 months continuous service	3 years from the date of issue
B	1.5 million	\$0.25	12 months continuous service	3 years from the date of issue

Performance Rights

1.5 million Performance Rights with two vesting conditions, the first being 18 months of continuous service with the Company, and the second being the Successful execution of a definitive agreement with a third party for the development and/or commercialisation of the Company's MSC-based therapy, where the combined value of upfront, clinical development, regulatory and commercial milestone payments equals or exceeds USD \$150 million.

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Paul Fry

Executive Director

PFry@neuroscientific.com

+61 422 001 188

Chris Achurch

Company Secretary

chris@westarcapital.com.au

+61 8 6268 2641

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company's research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.

Targeting Crohn's Disease with StemSmart™ Technology

Following the acquisition of Isopogen WA, NSB is prioritizing the application of its proprietary StemSmart technology through a Special Access Scheme (SAS) program targeting fistulising Crohn's disease—a severe and treatment-resistant form of the condition. If early outcomes from this access program are favourable, the Company intends to progress to a Phase 1/2 clinical trial to further evaluate safety and preliminary efficacy. This initiative aligns with NSB's broader strategy to obtain regulatory and

For personal use only

reimbursement approval for its mesenchymal stromal cell (MSC) therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn's disease, for whom current therapies remain inadequate.

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations.

For personal use only